Tomarchio V, Rigacci L, Annibali O
Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, Roma, 00128, Italy.
Research Unit of Hematology, Department of Medicine and Surgery, Università Campus Bio- Medico di Roma, Via Alvaro del Portillo, 21, Roma, 00128, Italy.
J Hematol Oncol. 2025 Apr 23;18(1):46. doi: 10.1186/s13045-025-01695-1.
Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in patients with heavily pretreated B-cell non-Hodgkin lymphoma (B-NHL), showing a tolerable toxicity profile predominantly associated with T-cell activation-related side effects. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of Large B Cell Lymphoma (LBCL), also in first line, from the ASH 2024 annual meeting (ASH 2024).
双特异性抗体（BsAbs）是一类创新的现成的T细胞重定向药物，被认为是治疗淋巴瘤最有前景的免疫治疗策略之一。值得注意的是，抗CD20×CD3双特异性抗体在预处理严重的B细胞非霍奇金淋巴瘤（B-NHL）患者中已显示出显著的单药治疗疗效，其毒性特征主要与T细胞激活相关的副作用有关，且耐受性良好。在本研究中，我们总结了美国血液学会2024年年会（ASH 2024）上关于CD20×CD3双特异性抗体治疗大B细胞淋巴瘤（LBCL）（包括一线治疗）的几篇最新报告。
